The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease.

ABSTRACT:

Context

Diabetic kidney disease (DKD) is the leading cause of end stage kidney disease (ESKD) and is associated with a considerably shortened lifespan. While glucose-lowering therapy targeting glycated hemoglobin (HbA1c) <7% is proven to reduce the risk of developing DKD, its effects on complications of DKD are unclear.

Objective

We examined the associations of HbA1c with risks of progression to ESKD and death within a clinic-based study of CKD. We hypothesized that higher HbA1c concentrations would be associated with increased risks of ESKD and death.

Design and setting

We studied 618 participants from the Seattle Kidney Study (mean eGFR 42 ml/min), 308 of whom had diabetes, and tested associations of baseline HbA1c with time to a composite outcome of initiation of r

SUBMITTER: Limkunakul C 

PROVIDER: S-EPMC6411440 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature